Roche Exit Wave’s Allele-Selective ASO in Huntington’s Disease

Company: Wave Life Sciences / Roche / Ionis Event type: Platform readthrough and competitive analysis Modality: Antisense oligonucleotide Asset: WVE-003 Disease area: Huntington’s disease Insilens signal strength: 3 / 5 Summary Roche’s discontinuation of tominersen in Huntington’s disease creates an important platform-level readthrough for Wave…